Evidence map›Paper›PMID 37656725›Full record

ArticlePloS one2023

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.

Trésor Zola Matuvanga, Joachim Mariën, Ynke Larivière, Bernard Isekah Osang'ir, Solange Milolo, Rachel Meta, Emmanuel Esanga, Vivi Maketa, Junior Matangila, Patrick Mitashi and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Trésor Zola MatuvangaTropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.ORCID 0009-0006-0418-2683
Joachim MariënDepartment of Biology, Evolutionary Ecology Group, University of Antwerp, Wilrijk, Antwerp, Belgium.
Ynke LarivièreVaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium.
Bernard Isekah Osang'irVaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium.
Solange MiloloTropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Rachel MetaTropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0003-3586-459X
Emmanuel EsangaDivision Provinciale de la Santé de la Tshuapa, Ministry of Health Hygiene and Prevention, Boende, Tshuapa, Democratic Republic of the Congo.
Vivi MaketaTropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Junior MatangilaTropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Patrick MitashiTropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Steve Ahuka MundekeDepartment of Virology, Institut National de Recherches Biomedicales, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Hypolite Muhindo-MavokoTropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Jean-Jacques Muyembe TamfumDepartment of Virology, Institut National de Recherches Biomedicales, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Pierre Van DammeVaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium.
Jean-Pierre Van GeertruydenDepartment of Family Medicine and Population Health, Global Health Institute, University of Antwerp, Wilrijk, Antwerp, Belgium.
University of Antwerp · BEUniversity of Kinshasa · CDNational Institute of Biomedical Research · CDMinistry of Public Health · CD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens.

methodsSerum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay.

resultsThe seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0-1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA.

conclusionIn contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.

Indexed as

Blood Group AntigensEbola VaccinesEbolavirusHemorrhagic Fever, EbolaAnimalsDemocratic Republic of the CongoHealth PersonnelHumansSeroepidemiologic StudiesBlood Group AntigensEbola Vaccines

Identifiers

PMID37656725
PMCPMC10473486
OpenAlexW4386365310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.